-+ 0.00%
-+ 0.00%
-+ 0.00%

Medivir Secures Extended US Patent for Liver Cancer Combination Therapy

MT Newswires·11/10/2026 06:53:15
Listen to the news
06:53 AM EST, 11/10/2026 (MT Newswires) -- The United States Patent and Trademark Office approved the intellectual property rights for Medivir's (MVIR.ST) fostroxacitabine bralpamide plus lenvatinib combination treatment for hepatocellular carcinoma and cancer metastases to the liver. The US regulator also granted a Patent Term Adjustment of 1,001 days to account for administrative delays during the application evaluation, extending the patent to at least January 2044 from April 2041, the pharmaceutical company said Tuesday.